UBS Group lowered shares of Integra Lifesciences (NASDAQ:IART) to a market perform rating in a report released on Tuesday, The Fly reports.

IART has been the topic of a number of other research reports. Zacks Investment Research raised shares of Integra Lifesciences from a sell rating to a hold rating in a research report on Tuesday, December 26th. TheStreet downgraded shares of Integra Lifesciences from a b rating to a c+ rating in a report on Thursday, October 26th. Oppenheimer restated a buy rating on shares of Integra Lifesciences in a report on Thursday, October 26th. Jefferies Group restated a buy rating and set a $56.00 target price on shares of Integra Lifesciences in a report on Sunday, October 29th. Finally, JPMorgan Chase & Co. downgraded shares of Integra Lifesciences from an overweight rating to a neutral rating and set a $44.00 target price on the stock. in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $53.64.

Shares of Integra Lifesciences (IART) opened at $46.55 on Tuesday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The company has a market cap of $3,701.78, a price-to-earnings ratio of 26.06, a PEG ratio of 1.57 and a beta of 0.65. Integra Lifesciences has a 1 year low of $40.51 and a 1 year high of $56.42.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.93 EPS. research analysts forecast that Integra Lifesciences will post 1.85 EPS for the current year.

In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Barbara B. Hill acquired 10,768 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was bought at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC increased its holdings in shares of Integra Lifesciences by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in shares of Integra Lifesciences by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Integra Lifesciences by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares during the last quarter. Whittier Trust Co. acquired a new position in shares of Integra Lifesciences in the third quarter valued at $169,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in shares of Integra Lifesciences in the second quarter valued at $174,000. Hedge funds and other institutional investors own 87.58% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.watchlistnews.com/integra-lifesciences-iart-downgraded-by-ubs-group-to-market-perform/1797076.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

The Fly

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with Analyst Ratings Network's FREE daily email newsletter.